{"id":3937,"date":"2025-03-31T18:11:53","date_gmt":"2025-03-31T18:11:53","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/efavirenz-txt\/"},"modified":"2025-03-31T18:11:53","modified_gmt":"2025-03-31T18:11:53","slug":"efavirenz-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/efavirenz-txt\/","title":{"rendered":"Efavirenz.txt"},"content":{"rendered":"

Efavirenz<\/h1>\n

CLINICAL USE <\/H3>
\nNon-nucleoside reverse transcriptase inhibitor:HIV infection in combination with other antiretroviral drugs

DOSE IN NORMAL RENAL FUNCTION <\/H3>600 mg once daily (tablets and capsules should be taken on an empty stomach to minimise side effects)Oral solution: 720 mg once daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :315.7<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :99.5\u201399.75<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <1<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :2\u20134<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :40\u201355 (multiple dosing); 52\u201376 (single dosing)\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Not dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antidepressants: concentration reduced by St John\u2019s wort \u2013 avoid concomitant use; concentration of sertraline reduced\n
  • Antifungals: itraconazole and voriconazole concentration reduced; voriconazole increases efavirenz concentration \u2013 reduce dose of efavirenz by 50% and increase dose of voriconazole to 400 mg twice daily; possibly reduces caspofungin concentration \u2013 may possibly need to increase caspofungin dose\n
  • Antipsychotics: possibly increased risk of ventricular arrhythmias with pimozide and sertindole \u2013 avoid concomitant use; possibly reduces aripiprazole concentration \u2013 increase aripiprazole doseAnxiolytics and hypnotics: risk of prolonged sedation with midazolam \u2013 avoid concomitant use\n
  • Antivirals: saquinavir concentration significantly reduced; concentration of amprenavir, darunavir, indinavir, lopinavir and atazanavir reduced \u2013 increase atazanavir dose; concentration reduced by nevirapine; monitor LFTs when used in combination with ritonavir\n
  • Ciclosporin: concentration of ciclosporin possibly reduced\n
  • Ergot alkaloids: risk of ergotism \u2013 avoid concomitant use\n
  • Grapefruit juice: concentration possibly increased

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Induces its own metabolism Metabolised by CYP450 3A4 and 2B6 systemsMonitor cholesterol levels as increases of
  • 10 to 20 <\/LI>% in total cholesterol have been reportedHalf-life of 10 hours in haemodialysis patients has been reported\n
  • Bioavailability of oral solution is less than that for capsules or tablets \u2013 therefore not interchangeable
    \n","protected":false},"excerpt":{"rendered":"

    Efavirenz CLINICAL USE Non-nucleoside reverse transcriptase inhibitor:HIV infection in combination<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3937","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3937"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3937\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}